• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

Hide Search
Shopping Cart
Show SearchSearch
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
    • LactRx App
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
    • Donate
  • Contact
  • Show SearchSearch

Belimumab (Benlysta®)

April 1, 2022

Selected References:

  • Auyeung-Kima DJ, et al. 2009. Developmental and peripostnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reproductive Toxicology; 28:443-455.
  • Beaulieu DB, et al. 2018. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin. Gastroenterol. Hepatol. 16, 99–105.
  • Benlysta® Prescribing Information. 2021. Available online at https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU.PDF
  • 2013. Use of intravenous (IV) benlysta in pregnant patients with systemic lupus erythematosus (SLE). As cited in Ostensen M. 2014. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann NY Acad Sci 1317: 32-38.
  • Julsgaard M, et al. 2016. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology, 151:110-119.
  • Kathpalia P, et al. 2016. Detectable drug levels in infants exposed to biologics: so what? Gastroenterology. 151:25–6.
  • Kao JH, et al. 2021. Pregnancy outcomes in patients treated with belimumab: Report from real-world experience. Semin Arthritis Rheum. 2021 Oct;51(5):963-968. doi: 10.1016/j.semarthrit.2021.06.005. Epub 2021 Jun 24. PMID: 34403811.
  • Martin Bortlik, et al. 2014. Impact of Anti–Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children, Inflammatory Bowel Diseases. 20(3):495–501.
  • Miller RK, et al. 2014. ABSTRACT. Preliminary Data from the Belimumab Pregnancy Registry: International Prospective Cohort Study of Pregnancy Outcomes. OTIS/ENTIS meeting, Toronto, Can.
  • Peart E, Clowse MEB. 2014. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. Curr Opin Rheumatol; 26:118-123.
  • Sandhu VK, et al. 2015. Monoclonal Antibodies, Systemic Lupus erythematosus, and Pregnancy. J Rheumatol; 42:728-730.
  • Skorpen, GC. et al. 2016. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. 75(5):795-810.

Footer

           

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Asthma
  • Coronavirus (COVID-19)
  • Crohn’s Disease
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Juvenile Idiopathic Arthritis
  • Multiple Sclerosis
  • Pertussis/Tdap vaccine (“Whooping Cough” vaccine)
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists
OTIS Logo

Copyright © 2023 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^